Background: Structural MRI measurements can contribute to the prediction of amyloid pathology in cognitively unimpaired (CU) individuals. In this work, we aimed at studying the predictive capacity, robustness, and generalizability of ML techniques to predict amyloid-ß pathology in CU individuals, as well as identifying key brain regions contributing to this prediction. Method: We included 653 and 250 CU individuals from the EPAD and ADNI studies, respectively, with available T1w MRI and CSF Aß42 measurements. Subjects were categorized as amyloid-ß positive (Aß+) or negative (Aß-) according to established cut-offs (CSF Aß42<1000pg/mL for EPAD and <880pg/mL for ADNI). Volumes and cortical thickness in regions of the Desikan-Kiliany atlas ...
Background: Plasma biomarkers have demonstrated excellent agreement with established markers of am...
Predicting Alzheimer's disease (AD) in individuals with some symptoms of cognitive decline may have ...
International audiencePredicting Alzheimer's disease (AD) in individuals with some symptoms of cogni...
Background Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of...
Background: With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (...
Background: With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (...
Background: With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (...
Background With the shift of research focus towards the pre-dementia stage of Alzheimer’s disease (A...
ObjectiveTo identify a neuroimaging signature predictive of brain amyloidosis as a screening tool to...
With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (AD), there i...
Background: Noninvasive identification of amyloid-β (Aβ) is important for better clinical management...
Biomarker assisted preclinical/early detection and intervention in Alzheimer’s disease (AD) may be t...
Introduction: The value of quantitative longitudinal and regional amyloid beta (Aβ) measurements in ...
© 2021, The Author(s).Predicting amyloid positivity in patients with mild cognitive impairment (MCI)...
Background: Plasma biomarkers have demonstrated excellent agreement with established markers of am...
Predicting Alzheimer's disease (AD) in individuals with some symptoms of cognitive decline may have ...
International audiencePredicting Alzheimer's disease (AD) in individuals with some symptoms of cogni...
Background Magnetic resonance imaging (MRI) has unveiled specific alterations at different stages of...
Background: With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (...
Background: With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (...
Background: With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (...
Background With the shift of research focus towards the pre-dementia stage of Alzheimer’s disease (A...
ObjectiveTo identify a neuroimaging signature predictive of brain amyloidosis as a screening tool to...
With the shift of research focus towards the pre-dementia stage of Alzheimer's disease (AD), there i...
Background: Noninvasive identification of amyloid-β (Aβ) is important for better clinical management...
Biomarker assisted preclinical/early detection and intervention in Alzheimer’s disease (AD) may be t...
Introduction: The value of quantitative longitudinal and regional amyloid beta (Aβ) measurements in ...
© 2021, The Author(s).Predicting amyloid positivity in patients with mild cognitive impairment (MCI)...
Background: Plasma biomarkers have demonstrated excellent agreement with established markers of am...
Predicting Alzheimer's disease (AD) in individuals with some symptoms of cognitive decline may have ...
International audiencePredicting Alzheimer's disease (AD) in individuals with some symptoms of cogni...